A Phase 1 interventional study of Omecamtiv mecarbil and Placebo in Healthy Volunteer, sponsored by Cytokinetics. Completed at 1 site in Japan. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-27.
Sponsored by Cytokinetics · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing omecamtiv mecarbil in Heart Failure — 1 open to participants now, 1 under way, 1 of them phase 3. omecamtiv mecarbil · Heart Failure.
Among the 14 studies testing omecamtiv mecarbil in Heart Failure, this one is the 7th largest by enrollment, is the only one that started in 2015, is one of 3 in phase 1, and was the 9th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.
Browse Heart Failure studies →1 of the 14 studies testing omecamtiv mecarbil in Heart Failure is open now, in 10 countries. Recruiting first, the newest first:
Cytokinetics · Sites in United States, Canada, China and 7 more countries
Ages 18–85
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 20 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2015.
This study's enrollment of 50 is below the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 48 across the 14 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 14 have an industry lead sponsor. The 1 most frequent:
Cytokinetics is the lead sponsor of 41 studies on the registry; 3 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 7 (64%) have results posted.
15 studies in Heart Failure by Cytokinetics: 2 open now, 2 under way, 1 of them phase 3. Of 11 finished, 8 (73%) have results posted.
Among the 15 studies in Heart Failure by Cytokinetics, this one is the 8th largest by enrollment, is the only one that started in 2015, is one of 3 in phase 1, and was the 9th registered.
Cytokinetics’s Heart Failure studies by the year they started, since 2005.
1 of the studies testing omecamtiv mecarbil in Heart Failure that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing omecamtiv mecarbil in Heart Failure, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Cytokinetics’s 15 in Heart Failure:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of omecamtiv mecarbil in healthy volunteers in Japan.
This study was conducted by Amgen as the IND holder, with Cytokinetics as a collaborator. Due to the termination of the collaboration agreement between Amgen and Cytokinetics in May 2021 and subsequent transfer of the omecamtiv mecarbil IND from Amgen to Cytokinetics, Cytokinetics is now listed as the sponsor.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo tablets twice a day (BID) in dosing period 1 (days 1 to 8) and in dosing period 2 (days 20 to 27).
Drug: Placebo
Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg or 37.5 mg BID in dosing period 2 (days 20 to 27) based on their day 8 predose omecamtiv mecarbil plasma concentration (Cpredose): If day 8 Cpredose was \< 200 ng/mL, participants received 37.5 mg BID; if day 8 Cpredose was ≥ 200 ng/mL or a day 8 PK value was not available participants continued to receive 25 mg BID.
Drug: Omecamtiv mecarbil
Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg or 50 mg BID in dosing period 2 (days 20 to 27) based on their day 8 predose omecamtiv mecarbil plasma concentration (Cpredose): If day 8 Cpredose was \< 200 ng/mL, participants received 50 mg BID; if day 8 Cpredose was ≥ 200 ng/mL or a day 8 PK value was not available participants continued to receive 25 mg BID.
Drug: Omecamtiv mecarbil
Omecamtiv mecarbil tablets for oral administration
Also known as: AMG 423
Matching placebo tablets
Dosing Period 1: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil After First and Last Dose in Period 1
Time frame: Day 1 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 8 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours after the morning dose.
Dosing Period 1: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil After First and Last Dose in Period 1
Time frame: Day 1 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 8 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours after the morning dose.
Dosing Period 1: Area Under the Concentration-time Curve for a Dosing Interval of 12 Hours (AUC0-12) for Omecamtiv Mecarbil After First and Last Dose in Period 1
Time frame: Day 1 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 8 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose.
Dosing Period 1: Predose Omecamtiv Mecarbil Plasma Concentration
Time frame: Day 8 predose
Dosing Period 1: Accumulation Ratio
Accumulation ratio calculated as the ratio of day 8 AUC(0-12) / day 1 AUC(0-12)
Time frame: Day 1 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 8 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose.
Dosing Period 2: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil After First and Last Dose in Period 2
Time frame: Day 20 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 27 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours after the morning dose.
Dosing Period 2: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil After First and Last Dose in Period 2
Time frame: Day 20 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 27 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours after the morning dose.
Dosing Period 2: AUC(0-12) for Omecamtiv Mecarbil After First and Last Dose in Period 2
Time frame: Day 20 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 27 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose.
Dosing Period 2: Predose Omecamtiv Mecarbil Plasma Concentration
Time frame: Day 27 predose
Dosing Period 2: Accumulation Ratio
Accumulation ratio calculated as the ratio of day 27 AUC(0-12) / day 20 AUC(0-12).
Time frame: Day 20 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose. Day 27 at 0 hours and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after the morning dose.
Number of Participants With Treatment-emergent Adverse Events
An adverse event is defined as any untoward medical occurrence in a clinical trial participant, including worsening of a preexisting medical condition. The event does not necessarily have a causal relationship with study treatment. A serious adverse event is defined as an adverse event that met at least 1 of the following serious criteria: * fatal * life threatening * required in patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event. Adverse events were graded for severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
Time frame: 35 days
Number of Participants With Grade 3 or Higher Laboratory Toxicities
Abnormal laboratory findings were graded for severity according to the NCI CTCAE version 4.0 according to the following guideline: * Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. * Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL). * Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. * Grade 4: Life-threatening consequences; urgent intervention indicated. * Grade 5: Death related to AE.
Time frame: 35 days
Maximum Increase From Baseline in Fridericia-Corrected QT Interval (QTcF) In Dosing Period 1
QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle as measured by electrocardiogram (ECG). Maximum increase from Period 1 baseline was categorized as: ≤ 30 milliseconds (ms) \> 30 to 60 ms \> 60 ms
Time frame: Day 1 predose and day 8
Maximum Increase From Baseline in Fridericia-Corrected QT Interval (QTcF) In Dosing Period 2
QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle as measured by ECG. Maximum increase from Period 2 baseline was categorized as: ≤ 30 ms \> 30 to 60 ms \> 60 ms
Time frame: Day 20 predose and Day 27
This study was conducted at a single center in Japan. Participants were enrolled from 13 November 2015 to 24 November 2015.
| Milestone | Placebo | Period 1 Group A: Omecamtiv Mecarbil 25 mg | Period 1 Group B: Omecamtiv Mecarbil 25 mg | Period 2 Group A: Omecamtiv Mecarbil 25 mg | Period 2 Group A: Omecamtiv Mecarbil 37.5 mg | Period 2 Group B: Omecamtiv Mecarbil 25 mg | Period 2 Group B: Omecamtiv Mecarbil 50 mg |
|---|---|---|---|---|---|---|---|
| Started | 10 | 20 | 20 | 0 | 0 | 0 | 0 |
| Completed | 10 | 20 | 20 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | Period 1 Group A: Omecamtiv Mecarbil 25 mg | Period 1 Group B: Omecamtiv Mecarbil 25 mg | Period 2 Group A: Omecamtiv Mecarbil 25 mg | Period 2 Group A: Omecamtiv Mecarbil 37.5 mg | Period 2 Group B: Omecamtiv Mecarbil 25 mg | Period 2 Group B: Omecamtiv Mecarbil 50 mg |
|---|---|---|---|---|---|---|---|
| Started | 10 | 0 | 0 | 7 | 13 | 7 | 13 |
| Completed | 10 | 0 | 0 | 7 | 13 | 7 | 12 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| ng/mL | Group A: Omecamtiv Mecarbil 25 mg | Group B: Omecamtiv Mecarbil 25 mg |
|---|---|---|
| After first dose on day 1 | 77.4 ± 21.6 | 79.5 ± 18.9 |
| After last dose on day 8 | 256 ± 71.2 | 259 ± 59.2 |
| hours | Group A: Omecamtiv Mecarbil 25 mg | Group B: Omecamtiv Mecarbil 25 mg |
|---|---|---|
| After first dose on day 1 | 4.0 (0.5 to 8.0) | 3.0 (0.5 to 8.0) |
| After last dose on day 8 | 2.0 (0.5 to 4.0) | 2.0 (0.5 to 8.0) |
| ng*hr/mL | Group A: Omecamtiv Mecarbil 25 mg | Group B: Omecamtiv Mecarbil 25 mg |
|---|---|---|
| After first dose on day 1 | 687 ± 210 | 677 ± 163 |
| After last dose on day 8 | 2570 ± 739 | 2670 ± 699 |
| ng/mL | Group A: Omecamtiv Mecarbil 25 mg | Group B: Omecamtiv Mecarbil 25 mg |
|---|---|---|
| Dosing Period 1: Predose Omecamtiv Mecarbil Plasma Concentration | 190 ± 58.5 | 192 ± 55.1 |
Accumulation ratio calculated as the ratio of day 8 AUC(0-12) / day 1 AUC(0-12)
| ratio | Group A: Omecamtiv Mecarbil 25 mg | Group B: Omecamtiv Mecarbil 25 mg |
|---|---|---|
| Dosing Period 1: Accumulation Ratio | 3.66 ± 0.89 | 3.79 ± 0.77 |
| ng/mL | Group A: Omecamtiv Mecarbil 25 mg / 25 mg | Group A: Omecamtiv Mecarbil 25 mg / 37.5 mg | Group B: Omecamtiv Mecarbil 25 mg / 25 mg | Group B: Omecamtiv Mecarbil 25 mg / 50 mg |
|---|---|---|---|---|
| After first dose on day 20 | 96.5 ± 27.2 | 107 ± 30.4 | 84.9 ± 30.0 | 154 ± 22.0 |
| After last dose on day 27 | 335 ± 32.0 | 341 ± 48.8 | 311 ± 54.2 | 537 ± 91.7 |
| hours | Group A: Omecamtiv Mecarbil 25 mg / 25 mg | Group A: Omecamtiv Mecarbil 25 mg / 37.5 mg | Group B: Omecamtiv Mecarbil 25 mg / 25 mg | Group B: Omecamtiv Mecarbil 25 mg / 50 mg |
|---|---|---|---|---|
| After first dose on day 20 | 4.0 (2.0 to 11) | 2.0 (0.5 to 6.0) | 4.0 (1.0 to 11) | 3.0 (0.5 to 6.0) |
| After last dose on day 27 | 2.0 (0.5 to 4.0) | 3.0 (0.5 to 4.0) | 4.0 (0.5 to 4.0) | 3.0 (0.5 to 4.0) |
| ng*hr/mL | Group A: Omecamtiv Mecarbil 25 mg / 25 mg | Group A: Omecamtiv Mecarbil 25 mg / 37.5 mg | Group B: Omecamtiv Mecarbil 25 mg / 25 mg | Group B: Omecamtiv Mecarbil 25 mg / 50 mg |
|---|---|---|---|---|
| After first dose on day 20 | 902 ± 220 | 950 ± 228 | 841 ± 403 | 1330 ± 217 |
| After last dose on day 27 | 3520 ± 505 | 3500 ± 519 | 3290 ± 662 | 5490 ± 1000 |
| ng/mL | Group A: Omecamtiv Mecarbil 25 mg / 25 mg | Group A: Omecamtiv Mecarbil 25 mg / 37.5 mg | Group B: Omecamtiv Mecarbil 25 mg / 25 mg | Group B: Omecamtiv Mecarbil 25 mg / 50 mg |
|---|---|---|---|---|
| Dosing Period 2: Predose Omecamtiv Mecarbil Plasma Concentration | 271 ± 44.8 | 256 ± 42.1 | 245 ± 43.3 | 401 ± 77.8 |
Accumulation ratio calculated as the ratio of day 27 AUC(0-12) / day 20 AUC(0-12).
| ratio | Group A: Omecamtiv Mecarbil 25 mg / 25 mg | Group A: Omecamtiv Mecarbil 25 mg / 37.5 mg | Group B: Omecamtiv Mecarbil 25 mg / 25 mg | Group B: Omecamtiv Mecarbil 25 mg / 50 mg |
|---|---|---|---|---|
| Dosing Period 2: Accumulation Ratio | 4.12 ± 1.28 | 3.81 ± 0.83 | 4.53 ± 1.19 | 4.11 ± 1.15 |
An adverse event is defined as any untoward medical occurrence in a clinical trial participant, including worsening of a preexisting medical condition. The event does not necessarily have a causal relationship with study treatment. A serious adverse event is defined as an adverse event that met at least 1 of the following serious criteria: * fatal * life threatening * required in patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event. Adverse events were graded for severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
| Participants | Placebo | Group A: Omecamtiv Mecarbil 25 mg / 25 mg | Group A: Omecamtiv Mecarbil 25 mg / 37.5 mg | Group B: Omecamtiv Mecarbil 25 mg / 25 mg | Group B: Omecamtiv Mecarbil 25 mg / 50 mg |
|---|---|---|---|---|---|
| Any treatment-emergent adverse event | 6 | 4 | 7 | 4 | 3 |
| Serious adverse events | 0 | 0 | 0 | 0 | 0 |
| TEAE leading to discontinuation of study drug | 0 | 0 | 0 | 0 | 1 |
| Severe adverse events | 0 | 0 | 0 | 1 | 1 |
| Life-threatening adverse events | 0 | 0 | 0 | 0 | 0 |
| Fatal adverse events | 0 | 0 | 0 | 0 | 0 |
Abnormal laboratory findings were graded for severity according to the NCI CTCAE version 4.0 according to the following guideline: * Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. * Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL). * Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. * Grade 4: Life-threatening consequences; urgent intervention indicated. * Grade 5: Death related to AE.
| Participants | Placebo | Group A: Omecamtiv Mecarbil 25 mg / 25 mg | Group A: Omecamtiv Mecarbil 25 mg / 37.5 mg | Group B: Omecamtiv Mecarbil 25 mg / 25 mg | Group B: Omecamtiv Mecarbil 25 mg / 50 mg |
|---|---|---|---|---|---|
| Number of Participants With Grade 3 or Higher Laboratory Toxicities | 0 | 0 | 0 | 0 | 0 |
QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle as measured by electrocardiogram (ECG). Maximum increase from Period 1 baseline was categorized as: ≤ 30 milliseconds (ms) \> 30 to 60 ms \> 60 ms
| Participants | Placebo | Group A: Omecamtiv Mecarbil 25 mg / 25 mg | Group A: Omecamtiv Mecarbil 25 mg / 37.5 mg | Group B: Omecamtiv Mecarbil 25 mg / 25 mg | Group B: Omecamtiv Mecarbil 25 mg / 50 mg |
|---|---|---|---|---|---|
| ≤ 30 ms | 10 | 7 | 13 | 7 | 13 |
| > 30 to 60 ms | 0 | 0 | 0 | 0 | 0 |
| > 60 ms | 0 | 0 | 0 | 0 | 0 |
QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle as measured by ECG. Maximum increase from Period 2 baseline was categorized as: ≤ 30 ms \> 30 to 60 ms \> 60 ms
| Participants | Placebo | Group A: Omecamtiv Mecarbil 25 mg / 25 mg | Group A: Omecamtiv Mecarbil 25 mg / 37.5 mg | Group B: Omecamtiv Mecarbil 25 mg / 25 mg | Group B: Omecamtiv Mecarbil 25 mg / 50 mg |
|---|---|---|---|---|---|
| ≤ 30 ms | 10 | 7 | 13 | 7 | 12 |
| > 30 to 60 ms | 0 | 0 | 0 | 0 | 0 |
| > 60 ms | 0 | 0 | 0 | 0 | 0 |
Collected over Period 1: Day 1 to day 19 Period 2: Day 20 to day 35. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period 1: Placebo | — | 0/10 (0%) | 2/10 (20%) |
| Period 1 Group A: OM 25 mg BID | — | 0/20 (0%) | 5/20 (25%) |
| Period 1 Group B: OM 25 mg BID | — | 0/20 (0%) | 3/20 (15%) |
| Period 2: Placebo | — | 0/10 (0%) | 4/10 (40%) |
| Period 2 Group A: OM 25 mg BID | — | 0/7 (0%) | 3/7 (42.9%) |
| Period 2 Group A: OM 37.5 mg BID | — | 0/13 (0%) | 3/13 (23.1%) |
| Period 2 Group B: OM 25 mg BID | — | 0/7 (0%) | 1/7 (14.3%) |
| Period 2 Group B: OM 50 mg BID | — | 0/13 (0%) | 3/13 (23.1%) |
| Event | Period 1: Placebo | Period 1 Group A: OM 25 mg BID | Period 1 Group B: OM 25 mg BID | Period 2: Placebo | Period 2 Group A: OM 25 mg BID | Period 2 Group A: OM 37.5 mg BID | Period 2 Group B: OM 25 mg BID | Period 2 Group B: OM 50 mg BID |
|---|---|---|---|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 0/10 | 2/20 | 0/20 | 2/10 | 1/7 | 3/13 | 0/7 | 1/13 |
| Injection site nerve damageGeneral disorders | 0/10 | 0/20 | 0/20 | 0/10 | 0/7 | 0/13 | 1/7 | 0/13 |
| Protein urine presentInvestigations | 0/10 | 0/20 | 0/20 | 0/10 | 1/7 | 0/13 | 0/7 | 0/13 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 0/10 | 2/20 | 0/20 | 0/10 | 1/7 | 0/13 | 0/7 | 0/13 |
| Orthostatic hypotensionVascular disorders | 0/10 | 0/20 | 0/20 | 0/10 | 1/7 | 0/13 | 0/7 | 0/13 |
| NauseaGastrointestinal disorders | 1/10 | 0/20 | 0/20 | 0/10 | 0/7 | 0/13 | 0/7 | 0/13 |
| Chest painGeneral disorders | 0/10 | 0/20 | 0/20 | 1/10 | 0/7 | 0/13 | 0/7 | 0/13 |
| Aspartate aminotransferase increasedInvestigations | 0/10 | 1/20 | 0/20 | 1/10 | 0/7 | 0/13 | 0/7 | 1/13 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/10 | 0/20 | 0/20 | 1/10 | 0/7 | 0/13 | 0/7 | 0/13 |
| Back painMusculoskeletal and connective tissue disorders | 1/10 | 0/20 | 0/20 | 0/10 | 0/7 | 0/13 | 0/7 | 0/13 |
All randomized participants
| Age, Continuous(years) | Placebo | Group A: Omecamtiv Mecarbil 25 mg / 37.5 mg | Group B: Omecamtiv Mecarbil 25 mg / 50 mg | Total |
|---|---|---|---|---|
| Mean | 29.2 ± 4.2 | 35.5 ± 7.6 | 27.3 ± 4.6 | 31.0 ± 7.0 |
| Sex: Female, Male(Participants) | Placebo | Group A: Omecamtiv Mecarbil 25 mg / 37.5 mg | Group B: Omecamtiv Mecarbil 25 mg / 50 mg | Total |
|---|---|---|---|---|
| Female | 3 | 6 | 6 | 15 |
| Male | 7 | 14 | 14 | 35 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Group A: Omecamtiv Mecarbil 25 mg / 37.5 mg | Group B: Omecamtiv Mecarbil 25 mg / 50 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 10 | 20 | 20 | 50 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Group A: Omecamtiv Mecarbil 25 mg / 37.5 mg | Group B: Omecamtiv Mecarbil 25 mg / 50 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 10 | 20 | 20 | 50 |
| Black or African American | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
Ran from Nov 2015 to primary completion in Jan 2016, 1 month.
Results were first posted in May 2021, 5 years 4 months after primary completion.
Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 1 month is below that.
Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Omecamtiv mecarbil